Promoter polymorphisms in the β-2 adrenergic receptor are associated with drug-induced gene expression changes and response in acute lymphoblastic leukemia

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 6, 2010, Pages 854-861

  Pottier, N ^a   Paugh, S W ^b   Ding, C ^b   Pei, D ^b   Yang, W ^b,c   Das, S ^c,d   Cook, E H ^c,e   Pui, C H ^b,f   Relling, M V ^b,c,f   Cheok, M H ^g   Evans, W E ^b,c,f  

^a France Institut Pasteur de Lille   (France)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c Pharmacogenetics of Anticancer Agents Research Group   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^g JEAN PIERRE AUBERT RESEARCH CENTER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; MERCAPTOPURINE; MESSENGER RNA; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CLINICAL TRIAL; DNA POLYMORPHISM; DRUG MEGADOSE; FEMALE; GENE EXPRESSION; GENOTYPE; GERM LINE; HAPLOTYPE; HUMAN; HUMAN CELL; LEUKEMIA CELL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROMOTER REGION; REMISSION; SCHOOL CHILD; TREATMENT RESPONSE; UPREGULATION;

EID: 78449269536     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.212     Document Type: Article

References (42)

1. Pui, C.H., Campana, d. & Evans, W.E. childhood acute lymphoblastic leukaemia-current status and future perspectives. Lancet Oncol. 2, 597-607 (2001).
2. Pui, C.H. & Evans, W.E. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 354, 166-178 (2006).
3. Simone, J.V. childhood leukemia as a model for cancer research: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 39, 4301-4307, (1979).
4. Pui, c.H. & Evans, W.E. Acute lymphoblastic leukemia. N. Engl. J. Med. 339, 605-615 (1998).
5. Evans, W.E. & Relling, M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487-491 (1999).
6. Evans, W.E. & Relling, M.V. Moving towards individualized medicine with pharmacogenomics. Nature 429, 464-468 (2004).
7. Cheok, M.H. et al. Treatment-specifc changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat. Genet. 34, 85-90 (2003).
8. Gu, C., Ma, Y.C., Benjamin, J., Littman, D., Chao, M.V. & Huang, X.Y. Apoptotic signaling through the beta -adrenergic receptor. A new Gs effector pathway. J. Biol. Chem. 275, 20726-20733 (2000).
9. Ma, Y.C. & Huang, X.Y. Novel signaling pathway through the beta-adrenergic receptor. Trends Cardiovasc. Med. 12, 46-49 (2002).
10. Scott, M.G., Swan, c., Wheatley, A.P. & Hall, I.P. Identifcation of novel polymorphisms within the promoter region of the human beta2 adrenergic receptor gene. Br. J. Pharmacol. 126, 841-844 (1999).
11. Liggett, S.B. beta(2)-adrenergic receptor pharmacogenetics. Am. J. Respir. Crit. Care Med. 161, S197-S201 (2000).
12. Liggett, S.B. Polymorphisms of the beta2-adrenergic receptor. N. Engl. J. Med. 346, 536-538 (2002).
13. Johnatty, S.E., Abdellatif, M., Shimmin, L., Clark, R.B. & Boerwinkle, E. Beta 2 adrenergic receptor 5′ haplotypes influence promoter activity. Br. J. Pharmacol. 137, 1213-1216 (2002).
14. Pui, C.H. et al.; Total Therapy Study XIIIB at St Jude children's Research Hospital. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude children's Research Hospital. Blood 104, 2690-2696 (2004).
15. Holleman, A. et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N. Engl. J. Med. 351, 533-542 (2004).
16. Lugthart, S. et al. Identifcation of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell 7, 375-386 (2005).
17. Lee, S.C. et al. Post-treatment tumor gene expression signatures are more predictive of treatment outcomes than baseline signatures in breast cancer. Pharmacogenet Genomics 19, 833-842 (2009).
18. Hamann, J. et al. Expression cloning and chromosomal mapping of the leukocyte activation antigen cd97, a new seven-span transmembrane molecule of the secretion receptor superfamily with an unusual extracellular domain. J. Immunol. 155, 1942-1950 (1995).
19. Hoang-Vu, C. et al. Regulation of cd97 protein in thyroid carcinoma. J. Clin. Endocrinol. Metab. 84, 1104-1109 (1999).
20. Clemmons, D.R. et al. Role of insulin-like growth factor binding proteins in the control of IGF actions. Prog. Growth Factor Res. 6, 357-366 (1995).
21. Kiefer, M.C. et al. characterization of recombinant human insulin-like growth factor binding proteins 4, 5, and 6 produced in yeast. J. Biol. Chem. 267, 12692-12699 (1992).
22. Bowman, K.G. & Bertozzi, C.R. carbohydrate sulfotransferases: mediators of extracellular communication. Chem. Biol. 6, R9-R22 (1999).
23. Brockhausen, I., Yang, J.M., Burchell, J., Whitehouse, c. & Taylor-Papadimitriou, J. Mechanisms underlying aberrant glycosylation of MUc1 mucin in breast cancer cells. Eur. J. Biochem. 233, 607-617 (1995).
24. Vavasseur, F. et al. O-glycan biosynthesis in human colorectal adenoma cells during progression to cancer. Eur. J. Biochem. 222, 415-424 (1994).
25. Yamori, T., Kimura, H., Stewart, K., Ota, D.M., Cleary, K.R. & Irimura, T. diferential production of high molecular weight sulfated glycoproteins in normal colonic mucosa, primary colon carcinoma, and metastases. Cancer Res. 47, 2741-2747 (1987).
26. Lipworth, B. et al. Beta2 adrenoceptor promoter polymorphisms: extended haplotypes and functional effects in peripheral blood mononuclear cells. Thorax 57, 61-66 (2002).
27. Panebra, A., Schwarb, M.R., Glinka, c.B. & Liggett, S.B. Allele-specifc binding of airway nuclear extracts to polymorphic beta2-adrenergic receptor 5' sequence. Am. J. Respir. Cell Mol. Biol. 36, 654-660 (2007).
28. Kamp, T., Liebl, B., Haen, E., Emmerich, B. & Hallek, M. deffects of beta 2-adrenergic signal transduction in chronic lymphocytic leukaemia: relationship to disease progression. Eur. J. Clin. Invest. 27, 121-127 (1997).
29. Yu, J. et al. Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell 12, 419-431 (2007).
30. Ma, Y.C., Huang, J., Ali, S., Lowry, W. & Huang, X.Y. Src tyrosine kinase is a novel direct effector of G proteins. Cell 102, 635-646 (2000).
31. Myklebust, J.H. et al. Activation of the cAMP signaling pathway increases apoptosis in human B-precursor cells and is associated with downregulation of Mcl-1 expression. J. Cell. Physiol. 180, 71-80 (1999).
32. Ogawa, R., Streif, M.B., Bugayenko, A. & Kato, G.J. Inhibition of PdE4 phosphodiesterase activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53, and p21(WAF1/cIP1) proteins in human acute lymphoblastic leukemia cells. Blood 99, 3390-3397 (2002).
33. Siegmund, B. et al. Phosphodiesterase type 4 inhibitor suppresses expression of anti-apoptotic members of the Bcl-2 family in B-cLL cells and induces caspase-dependent apoptosis. Leukemia 15, 1564-1571 (2001).
34. Thompson, E.B. et al. Glucocorticoids, oxysterols, and cAMP with glucocorticoids each cause apoptosis of cEM cells and suppress c-myc. J. Steroid Biochem. Mol. Biol. 69, 453-461 (1999).
35. Yan, L., Herrmann, V., Hofer, J.K. & Insel, P.A. beta-adrenergic receptor/cAMP-mediated signaling and apoptosis of S49 lymphoma cells. Am. J. Physiol., Cell Physiol. 279, c1665-c1674 (2000).
36. Srivastava, R.K., Srivastava, A.R., Cho-chung, Y.S. & Longo, d.L. Synergistic effects of retinoic acid and 8-cl-cAMP on apoptosis require caspase-3 activation in human ovarian cancer cells. Oncogene 18, 1755-1763 (1999).
37. Steinberg, R.A. & cofno, P. Two-dimensional gel analysis of cyclic AMP effects in cultured S49 mouse lymphoma cells: protein modifcations, inductions and repressions. Cell 18, 719-733 (1979).
38. Pui, C.H. et al. Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia (2009).
39. Pui, C.H. et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N. Engl. J. Med. 360, 2730-2741 (2009).
40. Yeoh, E.J. et al. classifcation, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profling. Cancer Cell 1, 133-143 (2002).
41. Silverman, L.B. et al. Improved outcome for children with acute lymphoblastic leukemia: results of dana-Farber consortium Protocol 91-01. Blood 97, 1211-1218 (2001).
42. Lipshutz, R.J., Fodor, S.P., Gingeras, T.R. & Lockhart, d.J. High density synthetic oligonucleotide arrays. Nat. Genet. 21, 20-24 (1999).